Retatrutide Phase 2 Trial: -28.7% Weight Loss Explained

Overview of the Retatrutide Phase 2 Trial

The Retatrutide Phase 2 trial (NCT04881760, Eli Lilly) enrolled 338 adults with overweight or obesity (BMI 27-50) across multiple international sites. This was a randomized, double-blind, placebo-controlled study evaluating 5 dose cohorts over 48 weeks.

The results published in the New England Journal of Medicine (2023) produced the most significant weight loss data ever recorded in a Phase 2 trial for any GLP-class compound.

Primary Results: Dose-Response Data

Dose

Weight Loss at 24 weeks

Weight Loss at 48 weeks

Placebo	-2.1%	-2.3%
1mg/week	-7.9%	-10.4%
2mg/week	-12.9%	-17.5%
4mg/week	-17.3%	-22.8%
8mg/week	-22.8%	-28.7%
12mg/week	-24.2%	~-26%	The 8mg dose produced -28.7% body weight at 48 weeks — and the weight loss trajectory had not plateaued, suggesting even greater loss with longer treatment duration. Comparison to Existing GLP Data	Compound	Best Result	Duration	Magnitude

Semaglutide (STEP 1)	-14.9%	68 weeks	Reference
Tirzepatide (SURMOUNT-1)	-20.9%	72 weeks	+6 percentage points
Retatrutide 8mg (Phase 2)	-28.7%	48 weeks	+13.8 percentage points

Retatrutide achieved ~14 percentage points more weight loss than semaglutide's best result, in 20 fewer weeks. The magnitude exceeds tirzepatide by ~8 percentage points.

Why Is the Effect So Much Larger?

The Glucagon Receptor Addition

Both semaglutide and tirzepatide rely on appetite suppression as the primary fat loss driver. Retatrutide adds the glucagon receptor — which activates two additional pathways that do not depend on eating less:

• Hepatic fat oxidation: Glucagon receptor activation directly upregulates beta-oxidation of fatty acids in liver hepatocytes. The liver burns stored fat regardless of caloric intake.

• Brown adipose thermogenesis: GcgR activation in brown adipose tissue increases uncoupled respiration (heat generation from fat burning). This increases total energy expenditure independently of exercise or appetite.

The net result: Retatrutide produces fat loss through three concurrent mechanisms — (1) appetite suppression, (2) direct hepatic fat burning, and (3) increased energy expenditure via BAT — while semaglutide uses primarily (1) alone.

Secondary Endpoints

The trial also reported:

• Waist circumference: -20.4 cm reduction at highest dose (48 weeks)
• Visceral fat: MRI substudy showed preferential visceral fat reduction
• Cardiometabolic markers: Significant improvements in triglycerides, blood pressure
• Adverse events: Dose-dependent GI events (nausea, vomiting) similar to other GLP compounds — most mild-moderate, predominantly during dose escalation

Practical Research Implications

For the Clavicular Stack, the Phase 2 data supports several design decisions:

• Starting at 2mg and escalating: The dose-response is linear — slower escalation reduces GI side effects while allowing adaptation
• BPC-157 co-administration: GI events peak during escalation; BPC-157's gastroprotection is most critical in weeks 1-12
• The 8mg maintenance target: Phase 2 shows 8mg produces a superior response to 12mg at 48 weeks — likely due to better tolerability allowing consistent administration

What Comes Next: Phase 3 Status

As of early 2026, Retatrutide Phase 3 trials (TRIUMPH program) are underway. These trials are evaluating cardiovascular outcomes (TRIUMPH-CVOT), longer-term weight loss trajectories, and maintenance after treatment cessation.

Research-grade Retatrutide (GLP-3 R) available from Clavicular Stack. For laboratory research use only.